- Home
- SES vs AMRN Comparison
SES vs AMRN Comparison
Compare SES & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- AMRN
- Stock Information
- Founded
- SES 2012
- AMRN 1989
- Country
- SES United States
- AMRN Ireland
- Employees
- SES N/A
- AMRN N/A
- Industry
- SES Auto Parts:O.E.M.
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- AMRN Health Care
- Exchange
- SES Nasdaq
- AMRN Nasdaq
- Market Cap
- SES 384.0M
- AMRN 317.1M
- IPO Year
- SES N/A
- AMRN 1993
- Fundamental
- Price
- SES $1.28
- AMRN $14.93
- Analyst Decision
- SES Buy
- AMRN Strong Sell
- Analyst Count
- SES 1
- AMRN 1
- Target Price
- SES $2.00
- AMRN $12.00
- AVG Volume (30 Days)
- SES 4.0M
- AMRN 50.5K
- Earning Date
- SES 10-30-2025
- AMRN 10-29-2025
- Dividend Yield
- SES N/A
- AMRN N/A
- EPS Growth
- SES N/A
- AMRN N/A
- EPS
- SES N/A
- AMRN N/A
- Revenue
- SES $11,360,000.00
- AMRN $219,361,000.00
- Revenue This Year
- SES $883.92
- AMRN N/A
- Revenue Next Year
- SES $159.98
- AMRN N/A
- P/E Ratio
- SES N/A
- AMRN N/A
- Revenue Growth
- SES N/A
- AMRN N/A
- 52 Week Low
- SES $0.20
- AMRN $7.08
- 52 Week High
- SES $2.53
- AMRN $17.49
- Technical
- Relative Strength Index (RSI)
- SES 61.30
- AMRN 51.27
- Support Level
- SES $1.05
- AMRN N/A
- Resistance Level
- SES $1.33
- AMRN $15.46
- Average True Range (ATR)
- SES 0.07
- AMRN 0.45
- MACD
- SES 0.02
- AMRN -0.59
- Stochastic Oscillator
- SES 81.67
- AMRN 94.61
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.